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therapy (p = 0.003) as compared to non-depressed patients.
Results of an extended-Cox proportional hazard model indicated
that the hazard to switch/augment therapy was 2.4 times more
for depressed patients as compared to non-depressed patients 
in the latter six-months of the follow-up period (p = 0.0005).
Depression was consistently found to be a signiﬁcant predictor
of adherence, with depressed patients being 3–6% less adherent
to their OHAs than non-depressed patients. CONCLUSION:
Depression signiﬁcantly impacts utilization patterns and adher-
ence to OHAs in patients with type-2 diabetes. This lack of
adherence may affect glycemic control and consequently inci-
dence of diabetes related complications. The study results imply
that depression screening and treatment may be included in the
protocol for management of type-2 diabetes patients.
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OBJECTIVE: Measure the effect of non-adherence to oral antidi-
abetic medications on total and diabetes-attributable health care
costs in a managed care population. METHODS: Using a large
managed care administrative claims database, all patients with a
prescription for an oral antidiabetic from January, 2000 through
June, 2001 were selected (n = 54,505) from among continuously
eligible patients age 18 years and older. Total and diabetes-
attributable costs were computed during one year of follow-up.
A non-adherence variable, the total number of days that each
patient was without antidiabetic medication, was computed. The
computation allowed for stashing of antidiabetics within classes
but not across classes (alpha-glucosidase, metformin, other 
secretagogues, sulfonylureas, thiazolidinediones). Multivariate
log-linear regressions were estimated for costs using adherence,
diabetes severity, overall comorbidity burden, hospitalization in
prior six-months, concomitant insulin use, patient initiating
antidiabetic therapy, insurance plan, and demographic variables.
RESULTS: Overall, total and diabetes-attributable costs
decreased with worsened adherence to oral antidiabetics.
However, for the most costly patients (top 40%, median annual
costs of $9391), there was a 1.66% increase in total costs for
each 30 additional days without oral medication. Only patients
with the top 10% of attributable costs had increased diabetes-
attributable costs with worsening adherence. After excluding the
cost of prescription antidiabetic medications, non-adherence
increased costs in all but the lowest-cost patients (bottom 30%).
The top 40%, with median non-drug attributable costs of $1339,
realized a 6.38% cost increase with each 30 days without med-
ication and the middle 30%, with median of $741, realized a
3.76% increase. CONCLUSIONS: During one year of follow-
up, non-adherence to oral antidiabetics increased total and dia-
betes-attributable costs for the most resource-intensive patients
but did not increase average costs for the population overall. For
the 70% of patients with the highest diabetes-attributable costs,
worsening adherence increased the medical services portion of
diabetes-attributable costs.
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OBJECTIVES: This study aims to evaluate medication adher-
ence, utilization and costs associated with American Pharmacist
Association’s (AphA) Diabetes Care Project. METHODS:
Patients with diabetes were assigned to an intervention or control
cohort based on enrollment in APhA’s Diabetes Care Project.
Individual patients were included if they had at least two claims
for diabetes medications and were continuously enrolled from
April 1, 2002 to March 31, 2004. Retrospective pre-post cohort
design, descriptive and multivariate modeling analyses were 
conducted to compare medication utilization between the two
cohorts. RESULTS: A total of 118 patients (37 in the interven-
tion and 81 in the comparison) were identiﬁed. There were no
signiﬁcant differences between the two cohorts in medication
possession ratio (MPR), pharmacy costs, and the number of 
prescriptions of diabetes drugs, ACE inhibitors, and needles at
baseline. During the 12-month post period, patients in the inter-
vention were more likely to have a prescription for test strips
(OR = 144.9, p < 0.0001) and needles (OR = 11.7, p < 0.0001).
Compared to the baseline period, patients with pharmacist inter-
vention had signiﬁcantly more prescriptions for test strips (0.68
vs. 5.32), diabetes medications (6.24 vs. 11.41), needles (1.27 vs.
4.24) and ACE inhibitors (1.68 vs. 3.03), a higher MPR with
diabetes drugs (0.67 vs. 0.96) and higher pharmacy costs ($689.9
vs. $1617.8), whereas patients in the comparison had no signif-
icant differences. CONCLUSIONS: APhA Diabetes Care Project
signiﬁcantly increased patients?adherence to therapy and uti-
lization for test strips, needles, diabetes medications and ACE
inhibitors. The increased adherence to therapy may offer both
clinical and cost beneﬁts to patients. (Acknowledgments: 
American Pharmacists Association; The Manitowoc Health Care
Coalition; Don F. Jabas Associates.)
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OBJECTIVE: To investigate the effects of a disease manage-
ment program on diabetic adults in a Medicaid population.
METHODS: This study was a retrospective database analysis of
diabetes-related costs and utilization and of overall costs. A pre-
post design with a concurrent control group was employed. To
ensure appropriate comparability, the study group and control
group were matched using propensity scoring techniques. Data
available for analysis spanned from July, 2000 to May, 2004,
while rolling enrollment period for the disease management
program occurred between October, 2002 and July, 2003.
RESULTS: From a potential pool of 2921 diabetics that were
identiﬁed within a Medicaid program, a study population of 388
was initially assessed for eligibility within counties that were 
targeted to implement the disease management program. After
applying exclusion criteria, 122 diabetics began enrollment
within the program. Ultimately, 32 diabetics completed the 12
month disease management program. Results indicated that
mean monthly diabetes-related medical costs per patient were
$190 in the pre-period and $225 in the post-period. Mean
monthly total medical costs per patient were $930 in the pre-
period and $939 in the post-period. Mean monthly pharmacy
costs per patient were $378 in the pre-period and $473 in the
post-period. Further multivariate analysis adjusted for demo-
graphic characteristics, initial utilization, and chronic disease
score. CONCLUSIONS: Higher costs in the post-period may be
associated with increased levels of care motivated by participa-
tion in the program. For a disease such as diabetes, the positive
long-term effects due to better care may not be apparent in the
short period of time during which the study data was gathered.
A longer-term analysis is warranted. In addition, a small pro-
portion of patients (8.2%) completed the full 12-month diabetes
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disease management program. As such, future efforts should be
developed to increase retention in disease management programs
designed for Medicaid recipients.
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THE EFFECT OF INSULIN TREATMENT ON HEALTH CARE
UTILIZATION IN TYPE-II DIABETES
Thiebaud P1, Nichol MB1, Patel BV2
1University of Southern California, School of Pharmacy, Los Angeles,
CA, USA; 2MedImpact Healthcare Systems, Inc, San Diego, CA, USA
OBJECTIVE: To evaluate the effect of insulin treatment on
health care utilization among type-II diabetics. More aggressive
glucose control treatment, particularly with insulin, is known to
slow diabetic patients’ disease progression. Does it also reduce
health care utilization and cost in the short run? METHODS:
Medical, pharmacy, and laboratory claims for 369 type-II dia-
betes patients enrolled in a single managed care plan were eval-
uated. Patients were continuously eligible for at least two years
between June, 2001 and June, 2004. Separate variables were
computed for each year. The propensity score (PS) calculated
with classiﬁcation and regression trees (C&RT) was used to cal-
culate the probability of receiving insulin treatment, using year
one health status, demographics, and HgA1c laboratory values.
These probabilities were then used as weights in the regression
of total health care costs and ambulatory costs in year two on
an array of variables including insulin use. RESULTS: Insulin
treatment does not beneﬁt all groups of patients equally. Patients
over the age of 60 beneﬁt signiﬁcantly from insulin treatment
with a reduction in total health care cost of 60.5% (p = 0.0007)
and a reduction in ambulatory cost of 60.9% (p = 0.0008) com-
pared to younger diabetic patients (age < 60). CONCLUSION:
Diabetic patients age 60 or above and the health care payers
would greatly beneﬁt from better glucose control through insulin
treatment.
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OBJECTIVES: Diabetes is a progressive disease that often
requires periodic intensiﬁcation of treatment to control hyper-
glycemia. The objective of this study is to evaluate therapy
changes after initiation of metformin and sulfonylurea combi-
nation therapy. METHODS: This was a retrospective analysis of
data derived from the IMS Mediplus UK primary care database.
Patients were selected using the following criteria: type-2 dia-
betes diagnosis, age ≥30 years at diagnosis, initiation of OHA
combination with MF and SU between January 1, 1997 and
March 31, 2003. Patients with prior insulin prescription were
excluded. RESULTS: A toal of 6616 patients were included, with
a mean age of 62.82 years (±12.12) and 56.3% of male; 2603
patients (39.39%) had a history of macrovascular events and
647 (9.79%) had microvascular events. Hypertension (78.39%)
and dyslipidemia (59.89%) were also common among these
patients. The average follow-up was about 36.7 months. After
three years of initiating metformin and sulfonylurea combination
therapy, 54.8% had changed their therapy, either by discontin-
uing one or both initial agents, adding a third oral agent or
receiving insulin. No patient remained on the initial combination
after 6.5 years. Approximately 8–11% of patients changed
therapy every six-months during the ﬁrst ﬁve-years. By the end
of two years, about 14.1% have required insulin therapy and
10% had switched to another OHA combination therapy.
Approximately 46.9% of patients were prescribed insulin
therapy after seven-years. CONCLUSION: In this cohort of 
diabetic patients managed by GPs in the UK, a large number 
of patients require additional oral anti-hyperglycemic agents or
insulin to manage their hyperglycemia. More effective therapies
are needed in order to better manage these patients.
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OBJECTIVE: To investigate factors associated with health care
cost saving in patients with diabetes to the California Medicaid
Populations (Medi-Cal). METHODS: A retrospective study was
conducted by using claims data from January, 1995 to Decem-
ber, 2000. Dependent variable was total health care cost. His-
torical data including demographic factors, health care cost and
utilization, diabetes drug treatment, follow-up services based on
diabetic guidelines, medication compliance, complications, and
comorbidities were used as independent variables. The general-
ized estimating equation method was used to analyze the panel
data. RESULTS: Various factors have a signiﬁcant association
with health care cost savings to MediCal. Patients taking both
insulin and oral hypoglycemic drugs or patients having drug dose
increased had health care costs higher by $1210 and $141,
respectively. Patients having oral hypoglycemic or insulin, anti-
hypertensive, or lipid lowering drugs added also had health care
costs higher by $264, $528, or $199, respectively. In addition,
patients having drugs changed to different classes or to insulin
had health care costs higher by $1018. However, patients having
one percent of medication compliance increased had health care
costs lower by $7 in next six-month period. Moreover, patients
having ofﬁce visits based on diabetic guidelines or patients
having glucose monitoring strip had health care costs lower by
$730 or $258 in next six-month period, respectively. In addition,
patients having lab tests [e.g., HbA1C test every six-months
($121), cholesterol check up every year ($472), or dilated eye
check-up every year ($260)] could lower costs in the future.
CONCLUSIONS: Medi-Cal policy makers may implement some
disease management programs or health policy on patients who
have drug treatment problems and patients without follow-up
services based on diabetic guidelines in order to improve patient
outcomes and decrease health care costs in the future.
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OBJECTIVE: To examine the relationship between patient’s
payment type and prescription drug costs for diabetic outpatients
at a regional hospital in southern Thailand. METHODS:
Patient’s proﬁle and prescription for 1454 outpatients who used
anti-diabetic drugs between August and September 2002 were
collected. The patient’s type of payment was divided into two
groups, which were patients who paid out-of-pocket and patients
who did not pay for their prescriptions. Descriptive and linear
regression analyses were used to examine the relationship.
RESULTS: Results showed that average drug costs per prescrip-
tion between patients who paid out-of-pocket and patients who
